Doban Bio, a leader in advanced regenerative medical technology, announced on the 30th that it has signed a contract with Dongnam Institute of Radiological & Medical Sciences for the 'anticancer immune cell (NK cell) therapy technology license.' It is expected to accelerate the development of innovative cancer treatments for solid tumor patients excluding pancreatic cancer.
Jung Hyun-jae, CEO of Doban Bio (left), and Lee Chang-hoon, Director of the Southeast Regional Radiation Medical Center, are posing for a commemorative photo after signing a technology licensing agreement for anticancer immune cell therapy. [Photo by Doban Bio]
Doban Bio has secured core technology to produce NK immune cell therapies using natural killer cells (NK cells) by utilizing Dongnam Institute of Radiological & Medical Sciences' patented method (Patent No. 10-2256272) for high-efficiency mass proliferation of natural killer cells isolated from whole blood.
NK cells are important immune cells that serve as the first line of defense in the human immune system. Unlike T cells, they can immediately eliminate cancer cells and virus-infected cells without prior antigen recognition.
Recently, as the number and function of NK cells in cancer patients decline, activating them has emerged as an important cancer treatment strategy. However, NK cells are difficult to proliferate in large quantities outside the body, limiting their clinical application.
The technology developed by Dongnam Institute of Radiological & Medical Sciences overcomes these limitations by enabling mass proliferation of high-purity NK cells using radiation technology. It can be applied to both autologous and allogeneic therapies and serves as a platform technology that can be expanded to large-scale culture of CAR-NK cells, a form of cell gene therapy.
Dongnam Institute of Radiological & Medical Sciences is a science and technology specialized hospital under the Ministry of Science and ICT, possessing excellent research personnel and advanced research resources in the fields of radiation-bio and medical sciences.
Doban Bio, a partner institution of Doban Korean Medicine Hospital which operates the Cancer Immunity Center and Regenerative Medicine Center, specializes in immune cell and stem cell research, leading the personalized immune care market. It is engaged in research and development of anticancer immune cell therapies, manufacturing of special culture media for immune cell therapy, and cell storage business.
Jung Hyun-jae, CEO of Doban Bio, stated, "NK cells can be applied to various cancer types, and when used in combination with existing anticancer treatments, their effectiveness is expected to increase. Going forward, based on the treatment know-how gained from the Cancer Immunity Center that integrates Western and Korean medicine as well as regenerative medicine at Doban Korean Medicine Hospital, we will lead innovative growth in the bio-health sector."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
